Lecanemab is an antibody that attaches to beta-amyloid proteins accumulated in the brain and allows the immune system to get rid of them.
(Shutterstock)
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Long COVID patients are taking desperate measures in the hope of getting better. It’s time to increase our focus on testing potential long COVID treatments in clinical trials.
This treatment would work by targeting the SARS-CoV-2 virus itself and stopping it in its tracks. The evidence we have so far is promising, but it’s still very early days.
New treatments target different stages of COVID-19, including before patients become sick enough to need a hospital.
Juan Monino via Getty Images
A year after it became clear that COVID-19 was becoming a pandemic, there is still no cure, but doctors have several innovative treatments. Some are keeping patients out of the hospital entirely.
The use of cannabis, though safer than many other drugs, is not entirely without risk.
AP Photo/David Zalubowski, file
Weed, though far less dangerous than many other drugs, is not entirely without risk. Some 59% of people treating pain with medical cannabis experience moderate to severe withdrawal symptoms
We are slowly figuring out which drugs and therapies are effective against the new coronavirus.
Anton Petrus / Getty Images
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
Testing in cells is an important and exciting first step.
elkor/E+ via Getty Images
Nevan Krogan, University of California, San Francisco
Researchers at the University of California, San Francisco, identified nine existing drugs that show promise to treat COVID-19. The proteins they target haven’t been tried before.
Will my surgery work? Well, it depends on who you ask.
from www.shutterstock.com
Professional societies of doctors, surgeons or physiotherapists are more likely to recommend against treatments provided by others, our new research shows.
Have our hopes of a drug treatment for dementia been dashed by drug company Pfizer giving up on research efforts?
from www.shutterstock.com
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco